NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JMACCT ID: JMA-IIA00073

Registered date:16/10/2011

Clinical Trial of bevacizumab in patients with retinopathy of prematurity

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedretinopathy of prematurity
Date of first enrollment15/06/2009
Target sample size40
Countries of recruitmentJapan
Study typeINTERVENTIONAL
Intervention(s)Intervention type:DRUG. Intervention1:bevacizumab, Dose form:INJECTION, Route of administration:OPHTHALMIC, intended dose regimen:once. Control intervention1:retinal photocoagulation, Dose form:DEVICE, Route of administration:INTRA-OCULAR.

Outcome(s)

Primary Outcomeretinal status. Timepoint:4 weeks,8 weeks, 3 months, 6 months, 12 months .
Secondary Outcome.

Key inclusion & exclusion criteria

Age minimumNo Limit
Age maximum<=6 MONTHS
GenderBOTH
Include criteriaPatients with retinopathy of prematurity admitted in Miyazaki University Hospital
Exclude criterianone

Related Information

Contact

public contact
Name Masumi Inadumi
Address Ophthalmology,5300 Kihara, Kiyotake, Miyazaki
Telephone +81-985-85-1510
E-mail nobunaoi@gmail.com
Affiliation School of Medicine, Miyazaki University
scientific contact
Name Nobuhisa Nao-i
Address Ophthalmology,5300 Kihara, Kiyotake, Miyazaki
Telephone +81-985-85-1510
E-mail
Affiliation School of Medicine, Miyazaki University